The European Commission has cleared €23 million of proposed funding for Novartis Italy to develop vaccines in developing countries. After its assessment for R&D&I aid (research, development and innovation), the Commission has found that the support addresses a genuine market failure and stimulates research in the EU. Novartis’ project will create innovative vaccines at affordable prices. The project is also supported by the Gates Foundation and is expected to incur €76.9 million in R&D over five years.
Full content: EC Press Release
Related content: Revision of the EU Competition Rules on Cooperation in Research & Development and Production: Scope for Further Improvement (Axel Gutermuth, Arnold & Porter)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI